Nuveen
SGP

Nuveen’s SpyGlass Pharma SGP Stock Holding History

Nuveen’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$326K Buy
+14,649
New +$318K ﹤0.01% 3468

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Nuveen's SGP Position: Q2 2026 in Review

Nuveen opened a new position in SpyGlass Pharma (SGP) in Q2 2026: 14,649 shares worth $326K. The stake represents ﹤0.01% of the portfolio and ranks #3468 among its holdings.

43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Nuveen held 14,649 shares of SpyGlass Pharma worth $326K as of Q2 2026.
  • SpyGlass Pharma was a new Nuveen position in Q2 2026.
  • SpyGlass Pharma made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3468 holding.
  • 43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.